The estimated Net Worth of Scott M Rocklage is at least $20.3 Million dollars as of 16 June 2020. Scott Rocklage owns over 120,164 units of Aprea Therapeutics stock worth over $244,607 and over the last 9 years Scott sold APRE stock worth over $20,008,461.
Scott has made over 4 trades of the Aprea Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently Scott sold 120,164 units of APRE stock worth $4,001,461 on 16 June 2020.
The largest trade Scott's ever made was selling 255,000 units of Aprea Therapeutics stock on 19 May 2020 worth over $8,963,250. On average, Scott trades about 50,690 units every 141 days since 2015. As of 16 June 2020 Scott still owns at least 75,965 units of Aprea Therapeutics stock.
You can see the complete history of Scott Rocklage stock trades at the bottom of the page.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... und John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: